Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism in this randomized controlled trial publication.

The researchers examined if calcium and vitamin D supplementation promote bone mineral accrual in boys with risperidone-induced hyperprolactinemia.

Who Took Part

By PubMed's age tags, the people studied were young children, children and teenagers, men only.

Anthropometric, dietary, physical activity, and psychiatric assessments were conducted at baseline and week 18 and 36.

Linear mixed-effects regression analysis examined the longitudinal effect of treatment on skeletal outcomes.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

Plasma prolactin and vitamin D concentrations were measured at baseline and week 36.

Total body less head bone mineral content (BMC) and radius trabecular bone mineral density (BMD) were measured at baseline, week 18, and week 36, using dual-energy X-ray absorptiometry and peripheral quantitative computed tomography, respectively.

What Was Measured

Topics PubMed links to this paper include Absorptiometry, Photon, Antipsychotic Agents, Bone Density, Calcium Carbonate, Calcium, Dietary, Cholecalciferol and Dietary Supplements.

The authors tagged it with the keywords bone mass, children, hyperprolactinemia, risperidone and vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with hyperparathyroidism.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Journal of child and adolescent psychopharmacology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.